A cost-of-illness study of lyme disease in the United States

Clinical Therapeutics

Volumn 20, Issue 5, 1998, Pages 993-1008

  Maes, Edith ^a,c   Lecomte, Pascal ^a   Ray, Nancy ^b  

^a Lewin Group   (Belgium)

^b UNITED BIOSOURCE CORPORATION   (United States)

^c MHSM   (Belgium)

Author keywords

Cost of illness; Economic burden; Lyme disease; United States

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC THERAPY; ARTICLE; CLINICAL FEATURE; COST OF ILLNESS; DISEASE COURSE; DRUG COST; ECONOMIC ASPECT; HUMAN; LYME DISEASE; UNITED STATES; VACCINATION;

EID: 0031729329     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(98)80081-7     Document Type: Article

References (34)

1. Sigal LH. Anxiety and persistence of Lyme disease. Am J Med. 1995;98(Suppl 4A):74S-78S.
2. Shapiro ED, Gerber MA, Holabird NB, et al. A controlled trial of antimicrobial prophylaxis for Lyme disease after deer-tick bites. NEJM. 1992;327:1769-1773.
3. Melski JW, Reed KD, Mitchell PD, Barth GD. Primary and secondary erythema migrans in central Wisconsin. Arch Dermatol. 1993;129:709-716.
4. Gerber MA, Shapiro ED, Burke GS, et al. Lyme disease in children in southeastern Connecticut. Pediatric Lyme Disease Study Group. NEJM. 1996;335:1270-1274.
5. Nadelman RB, Nowakowski J, Forseter G, et al. The clinical spectrum of early Lyme borreliosis in patients with culture-confirmed erythema migrans. Am J Med. 1996;100:502-508.
6. Reid NG. The Delphi technique, its contribution to the evaluation of professional practice. In: Ellis R, ed. Professional Competence and Quality Assurance in the Caring Professions. London: Croom Helm; 1988.
7. Evans C. The use of consensus methods and expert panels in pharmacoeconomic studies. Practical applications and methodological shortcomings. PharmacoEconomics. 1997;12:121-129.
8. Linstone HA, Turoff M, eds. The Delphi Method: Techniques and Applications. Reading, Mass: Addison-Wesley Publishing Co; 1975.
9. Martin JP. The precision of Delphi estimates. Tech Forecasting. 1970;3:293-299.
10. Oddone EZ, Samsa G, Matchar DB. Global judgments versus decision-model-facilitated judgments: Are experts internally consistent? Med Decis Mak. 1994;14:19-26.
11. Gordon JF, Helmer O. Report on a Long Range Forecasting Study. Rand Paper P-2982. Santa Monica, Calif: Rand Corp; September 1964.
12. Lightfoot RW Jr, Luft BJ, Rahn DW, et al. Empiric parenteral antibiotic treatment of patients with fibromyalgia and fatigue and a positive serologic result for Lyme disease. A cost-effectiveness analysis. Ann Intern Med. 1993;119:503-509.
13. The International Classification of Diseases, 9th Revision, Clinical Modification, ICD-9-CM. 4th ed. DHHS publication no. 91-1260. Rockville, Md: US Health Care Financing Administration; 1991.
14. Merenstein GB, Kaplan DW, Rosenberg AA. Handbook of Pediatrics. 17th ed. East Norwalk, Conn: Appleton & Lange; 1994: 376-377.
15. Committee on Infectious Diseases, American Academy of Pediatrics. 1994 Red Book: Report of the Committee on Infectious Diseases. 23rd ed. Elk Grove Village, Ill: American Academy of Pediatrics; 1994:541-600.
16. Lyme disease - United States, 1993. MMWR. 1994;43:564-567.
17. Lyme disease - United States, 1994. MMWR. 1995;44:459-462.
18. Lyme disease - United States, 1995. MMWR. 1996;45:481-484.
19. Lyme disease - United States, 1996. MMWR. 1997;46:531-535.
20. Pauly MV, Medaglia M, Jung GT. The Economic Costs of Newly Diagnosed Lyme Disease. Final Report. Philadelphia, Pa: University of Pennsylvania; July 1990.
21. Magid D, Schwartz B, Craft J, Schwartz JS. Prevention of Lyme disease after tick bites. A cost-effectiveness analysis. NEJM. 1992;327:534-541.
22. Dressler F, Whalen JA, Reinhart BN, Steere AC. Western blotting in the serodiagnosis of Lyme disease. J Infect Dis. 1993;167:392-400.
23. Edmond MB, Nettleman MD. Lyme disease. Travel Med Advisor. 1995;35:1-19.
24. Schoen RT. Identification of Lyme disease. Rheum Dis Clin North Am. 1994; 20:361-369.
25. Sigal LH. Lyme disease: Testing and treatment. Rheum Dis Clin North Am. 1993; 19:79-93.
26. Steere AC, Taylor E, McHugh GL, Logigian EL. The overdiagnosis of Lyme disease. JAMA. 1993;269:1812-1816.
27. Public Use Data Tape Documentation, Part 1. National Health Interview Survey. Hyattsville, Md: National Center for Health Statistics; 1994.
28. Max W, Rice DP, MacKenzie EJ. The lifetime cost of injury. Inquiry. 1990;27: 332-343.
29. Employment and Earnings. Bulletin 2307. Washington, DC: US Bureau of Labor Statistics; January 1995.
30. Katz D, Welch G. Discounting in cost-effectiveness analysis of healthcare programmes. PharmacoEconomics. 1993;3: 276-285.
31. Siegel JE, Torrance GW, Russell LB, et al. Guidelines for pharmacoeconomic studies: Recommendations from the Panel on Cost-Effectiveness in Health and Medicine. PharmacoEconomics. 1997;11: 159-168.
32. Statistical Abstract of the United States: 1994. 114th ed. Washington, DC: US Bureau of the Census; 1994.
33. Physician reporting of Lyme disease - Connecticut, 1991-1992. MMWR. 1993; 42:348-350.
34. Strickland GT, Karp AC, Mathews A, Peña CA. Utilization and cost of serologic tests for Lyme disease in Maryland. J Infect Dis. 1997;176:819-821.